期刊文献+

三种药物联合治疗晚期胃癌的近期疗效和不良反应 被引量:1

下载PDF
导出
摘要 目的:观察奥沙利铂(L-OHP)联合氟尿嘧啶(5-Fu)和亚叶酸钙(CF)静脉滴注治疗晚期胃癌的近期疗效和不良反应。方法:85例晚期胃癌患者,第1天采用L-OHP100mg/m2,静脉滴注2h,CF200mg/m2,静脉滴注2h后(d1-5),5-Fu500mg/m2静脉滴注,(d1-5)。3周为1周期,每个病人接受2~4个周期。结果:全组完全缓解15例,部分缓解28例,近期有效率50.5%,不良反应主要为轻度Ⅰ°~Ⅱ°消化道反应及周围神经毒性等。结论:奥沙利铂联系5-氟尿嘧啶和亚叶酸钙治疗晚期胃癌的近期疗效较好,不良反应轻微,适合年老体弱病人,值得进一步研究。
作者 董宇慧
出处 《包头医学》 2009年第1期31-33,共3页 Journal of Baotou Medicine
  • 相关文献

参考文献10

  • 1剧际昌主编.实用肿瘤内科学[M].第二版.北京:人民卫生出版社.2003.589-591.
  • 2沈琳 金懋林 张晓东 等.奥沙利铂联合表阿霉素和5-Fu/CF治疗晚期胃癌的临床研究.中华肿瘤杂志,2003,25(2):172-174.
  • 3Louver C. Andre T, Tigaud JM, at al. Phase Ⅱ study of oxalip latin,fluorouracil, and folinic acid in locally advanced ormetastatic gastric cancer palients. J CliOncol. 2002, 20(23): 4543 - 4548.
  • 4Kim DY, Kim JH. Lee SH. et al. Phase Ⅱ study of oxaliplatin. 5 -fluorouracil and leucovorin in p reviously p latinum-treated patientswith ad2vanced gastric cancer. Ann Oncol. 2003,14 (3): 383 -387.
  • 5Al- Batran SE. Jaeger E, Jaeger D, et al. Oxalip latin, 5 fluorouracil and leucoworin every two weeks in patientswith advanced gastric cancer; prelinlinary results of amulticenter, phase Ⅱ study. Proc Am Soc Clin Oncol. 2003, 22: 1128.
  • 6Cavanna L, Berte R, Bernuzzi P, el al. Oxalip latin, in combination with 5-fluorouracil(5-Fu) and leucovorin (LV) in patients with advanced ormetastatic gastric cancer (A/MGC). Poc Am Soc Clin Oncol. 2003,22: 1369.
  • 7周建明,龚振夏,谭清和,陈志云.不同方法输注氟脲嘧啶、亚叶酸钙联合奥沙利铂治疗晚期消化道肿瘤的临床研究[J].临床肿瘤学杂志,2003,8(6):436-438. 被引量:19
  • 8王竞,王金万.胃癌治疗进展[J].癌症进展,2004,2(2):88-93. 被引量:37
  • 9周际吕主编.实用肿瘤内科学[M].第二版.北京:人民卫生出版社,2003.301-304.
  • 10Eriguchi M, Osada I, Fujii X, ct al. Pilot study for preopcrativeadministration of L-OHP to Patients with advanced scirrhous type gastric cancer [J]. Biomed Pharmacother. 1997, 51(5) :217 -220.

二级参考文献27

  • 1[1]Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer:Epidemiology, pathology and treatment. Annals of Oncology,2003, 14 (Suppl 2) :ii31
  • 2[2]Frederick LG, David LP, Irvin DF, et al. AJCC Cancer Staging Manual. 6th. ed, New York: Springer, 2002, 99
  • 3[3]Hundahl SA, Menck HR, Mansour EG, et al. The national cancer database report on gastric carcinoma. Cancer, 1997, 80: 2333
  • 4[4]Spataro V, Genoni M, Maurer C, et al. Stomach cancer: 10years' experience with surgical treatment and possibilities for improving the prognosis. Helv Chir Acta, 1993, 59:589
  • 5[5]Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345:725
  • 6[6]Bajetta E, Buzzoni R, Mariani E, et al. Adjuvant chemotherapy in gastric cancer: 5 - year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Annals of Oncology, 2002, 13:299
  • 7[7]Falcone A. Future strategies and adjuvant treatment of gastric cancer. Annals of Oncology, 2003, 14 (Suppl 2) :ii45
  • 8[8]Roth AD, Allal AS, Brundler MA, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: A phase Ⅰ -Ⅱ study. Annals of Oncology, 2003, 14:110
  • 9[9]Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg, 2002 6 (2) :212 (discussion 223)
  • 10[10]Gimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 1997, 8:1

共引文献56

同被引文献6

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部